Advances in Single-Cell Isolation
In her article “Advances in Single-Cell Isolation” on Biocompare, Caitlin Smith highlights recent improvements that have made single-cell studies more efficient and precise. Paul Steinberg, Chief Commercial Officer at Lightcast, notes that key elements for optimizing single-cell research include flexibility, speed, and throughput. As single-cell innovations become more widely available, the range of applications is also broadening. The expansion of single-cell technologies beyond transcriptomics and into functional assays is critical to elucidating biological signatures. Jason McKinney, Senior Director of Application Support at LevitasBio®, describes how influential sample preparation methods can be in maintaining native biology. The article explores both established and emerging single-cell isolation methods and the advancements driving this field forward. • Manual picking & laser capture microdissection• Fluorescence- and magnetic- activated cell sorting• Levitation Technology• Microfluidics• Image-based droplets Read the full article here.
Psomagen Adds LevitasBio’s Technology for Single-Cell Applications
Psomagen has announced the expansion of its single-cell capabilities by integrating the LevitasBio LeviCell EOS system into its service. This cutting-edge technology is a solution of choice to enhance the gentle purification process before single-cell sequencing, supporting clients’ needs for consistent, high-quality data. Alongside this, Psomagen has also incorporated Parse Biosciences into its single-cell portfolio, further strengthening its commitment to advanced cellular research. From their press release:Other recent additions to Psomagen’s single-cell capabilities include the LeviCell EOS from LevitasBio. This system provides a gentle purification workflow prior to single-cell sequencing. This step is ideal for removing dead cells following cryopreservation, removing debris during nuclei isolation, and removing ambient RNA or other unwanted signal from a cell suspension. Cleaner samples yield cleaner data and less wasted sequencing costs. “Sample quality is paramount to generating high quality, reproducible data,” says Linda Orzolek. “Psomagen recognizes the importance of offering a variety of options for our clients to ensure we meet their needs and the needs of their samples. If you come to us with a problem or a goal, we want to have not just a solution, but the RIGHT solution for your specific research, and that means expanding our services across multiple platforms and offering clients the flexibility that they need.” Read the full article here. About Psomagen Psomagen, Inc., formerly Macrogen Corp, is a North American integrative omics solutions and contract laboratory services provider. The company makes cutting-edge technology and data analysis accessible to the clinical and academic markets. With both CLIA-certified and CAP-accredited facilities, their team delivers only the highest-quality integrative multi-omics data using best-in-class DNA, RNA, and protein analysis systems. In conjunction with its bioinformatics capabilities, Psomagen offers a path to insights that is both simple and affordable. Learn more at psomagen.com.
GEN’s “Multiomic Mosaics” by Mike May, PhD: LevitasBio’s approach stands out for its sample preparation ‘gentler process’
In the GEN article “Multiomic Mosaics | Cell by Cell, Pixel by Pixel,” Mike May, PhD, delves into single-cell and spatial omics technologies, emphasizing the importance of innovative supporting technologies that ensure researchers obtain the highest quality data, leading to reliable and reproducible results. He highlights sample preparation as a crucial factor for achieving superior outcomes. Among the solutions discussed, LevitasBio’s approach stands out for its ‘gentler process,’ which enhances data purity by effectively eliminating noise from dead cells and debris commonly found in many cellular samples. Read the full article here.
The Single-Cell World Podcast: Levitation Technology – A Gentle Approach to Viable Cells and Nuclei Isolation
In this episode of the Single-Cell World podcast, hosted by Catia Moutinho, she interviews Kevin Travers, PhD, Senior Vice President of R&D at LevitasBio. They discuss LevitasBio’s label-free technology, which not only optimizes results for single-cell sequencing experiments but also serves as a crucial sample preparation step for any analytical or cell-based assay. Listen to the episode here. “What happens normally with other methods… they make us lose a lot of cells. Yes, we get a lot of dead cells and a lot of debris out but also live cells out. At the end, we do not have enough live cells to do the experiment.” Catia Moutinho, host of The Single-Cell World Podcast
Cytiva and LevitasBio join forces to transform single-cell workflow and accelerate therapeutic development
Two leading life sciences companies, Cytiva and LevitasBio, are collaborating to deliver an innovative single-cell workflow for genomics researchers in academia and industry. This collaboration marks a significant milestone in improving how samples are prepared, enabling researchers to more quickly perform tasks like breaking down tissues and purifying individual cell suspensions for single-cell analysis and other downstream applications. This is particularly important for advancing personalized medicine by providing insights into disease mechanisms and therapeutic targets, supporting oncology research, and accelerating scientific discovery. Stephen Bell, President, Discovery & Medical, Cytiva, says: ” Our collaboration is rooted in the shared goal of enabling breakthrough discoveries in Life Sciences research that advance and accelerate therapeutic developments. By combining the strengths of our products with LevitasBio, we aim to empower researchers with a more efficient and gentle approach to sample preparation.” Single-cell analysis plays a pivotal role in advancing therapeutic approaches, particularly in cancer research. Cytiva’s and LevitasBio’s expertise and technologies will be used to create a streamlined, semi-automated workflow solution. This will reduce single-cell damage or stress and improve overall single-cell health—all critical elements for producing viable samples for use in subsequent stages of genetic studies or other downstream cell-based assays. Martin Pieprzyk, CEO, LevitasBio, says: “The VIA Extractor and LeviCell platform offers a more complete approach to tissue dissociation and single-cell suspension cleanup, which better enables researchers to develop innovative solutions in the personalized medicine space. Through this pioneering effort, we’re taking a significant step towards facilitating breakthroughs in research and translational applications, aligning with our commitment to driving innovation in the life sciences industry.” The key technologies at the forefront of this collaboration are the VIA Extractor from Cytiva and the LeviCell 1.0 and LeviCell EOS systems from LevitasBio. See the products in action: VIA Extractor | LeviCell EOS system Trademark statement: VIA Extractor is a trademark of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. © 2020-2024 Cytiva. About Cytiva At Cytiva, our mission is to advance and accelerate the development of therapeutics. With nearly 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at cytiva.com. About LevitasBio At LevitasBio, our mission is to drive scientific progress and enhance human health through cutting-edge techniques in sample preparation and cellular analysis. Our exclusive label-free Levitation Technology represents a transformative breakthrough, preserving native cellular states, ensuring sample quality, and empowering researchers. We redefine research with a new standard, pioneering new discoveries across scientific disciplines. Join us on this journey to advance science and elevate human well-being. Media contact Cytiva: James [email protected] Media contact LevitasBio: Melissa Ma [email protected]
LevitasBio launches LeviCell EOS system for higher throughput cell isolation and enrichment through Levitation Technology
Original Source: Planet Innovation Author: Suraya Saleh / Marketing Communications Manager at Planet Innovation LevitasBio® has partnered with Planet Innovation to design and manufacture its groundbreaking new LeviCell® EOS system for cell isolation and enrichment during sample preparation. The LeviCell EOS launched in the middle of the year, with strong early sales and several units already installed at top research laboratories around the U.S. The LeviCell EOS system uses the same revolutionary Levitation Technology as its predecessor, LeviCell 1.0, to enrich cell populations without altering, stressing or damaging cells – allowing researchers access to higher-quality samples for downstream analysis. It is compatible with any cell type and sample source, meaning it can be used for research in a wide range of industries, including cell and gene therapy, and pharmaceutical drug development. With the same fast 3-step, 20-minute workflow as LeviCell 1.0, the LeviCell EOS now provides higher throughput to enable researchers to run four samples at once. To drive higher throughput to further scale there is the ability to connect up to four modules in parallel. New analysis software allows users to manage all instruments from a central control hub, and view the cells moving through the separation channel in real time. One of the core requirements from LevitasBio was that the instrument be designed as a flexible platform, with a core magnet and cartridge interface submodule that can be swapped out by users to suit their needs. A standard core module is currently available, with a new temperature-controlled module scheduled for release in coming months. The need for a temperature-controlled module was driven by user feedback on the LeviCell 1.0. Martin Pieprzyk, CEO of LevitasBio, said: “LevitasBio is changing the landscape of how researchers conduct their experiments. Building on the success of the LeviCell 1.0, the new LeviCell EOS system paves the way for fully integrated approaches to sample processing and accurate characterization at scaled throughputs. This marks a profound shift in how scientists work with their samples.” He added: “Planet Innovation has been a great partner throughout the development and into manufacturing. They’ve been very supportive, flexible and understanding of our business needs. We’ve had one of PI’s operational consultants, Sam Lui, embedded in our business throughout the whole process, which has been a huge benefit. Sam has a far deeper understanding of our product than you would normally expect from a service provider and this was invaluable throughout the development and now as we move into production and installation at customer sites.” Nathan Ray, Strategic Partner Manager at PI, commented: “PI has been working with LevitasBio as their design and manufacturing partner for almost four years now, and after the success of LeviCell 1.0, we were excited to have the opportunity to work with the team again on the EOS system. While the core tech is the same magnetic separation, the EOS is a more advanced product with a lot of great technology under the hood, including an expanded optics module, thermal control and a really easy-to-use interface. It’s a great product and we’re very happy to see this is being recognized by LevitasBio’s customers.”
LevitasBio Launches LeviSelect Suite of Cell Depletion & Enrichment Kits
New Product Line Delivers Major Advance in Immunology Research MENLO PARK, CA – LevitasBio, Inc. (levitasbio.com), a premier end-to-end sample processing and cellular analysis provider to the life sciences market, unveils a suite of LeviSelect™ cell depletion and enrichment kits for immunology research. LeviSelect Kits are a targeted expansion of the revolutionary LeviCell™ Advanced Workflow fully integrated protocol that delivers an important new approach to cellular isolation and analysis, offering: For oncology or immuno-oncology research, LeviSelect CD45 Depletion Kits provide a highly effective method for the enrichment of pure tumor cells enabling characterization for drug discovery and biomarker identification. LeviSelect Immune Kits support target selection of the immune subpopulations required for downstream cell analysis or further subsetting. Researchers can enrich hematopoietic populations quickly without lengthy workflows or potential cell activation. Now T Cells, B Cells, NK Cell and Monocytes can be enriched simultaneously with viable cell enrichment in an untouched and unbiased manner. Future LeviSelect kits will include subtypes from these major populations. “With the immediate launch of seven LeviSelect Kits—and six more available via our Early Access program—LevitasBio is enabling the streamline enrichment of these cells for downstream cell-based assays or immune profiling studies,” stated Martin Pieprzyk, CEO of LevitasBio. “This is highly impactful to catalyze novel discoveries in both academic and biopharma discovery research.” Researchers, scientists, and labs who would like exclusive, priority access to future LeviSelect Kits can join the LevitasBio Early Access Program at http://levitasbio.com/early-access-program. ### LevitasBio —True Biology Begins Here Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained. Download PR
LevitasBio Strengthens its C-Suite
Two Industry Veterans Join Already Strong Team MENLO Park – LevitasBio, Inc., a premier end-to-end sample processing and cellular analysis provider to the life sciences market, announced the hiring of Dominique Remy-Renou as its Senior Vice President of Global Commercial Operations of LevitasBio Europe BV, and the appointment of Greg Herrema to its Board of Directors. The addition of two Life Sciences veterans bring decades of biotech industry expertise and a history of proven success to LevitasBio’s already strong leadership team and board. Dominique Remy-Renou, Senior Vice President of Global Commercial Operations, LevitasBio Europe BVMs. Remy-Renou has over 30 years’ experience leading, building, developing and managing global field operations in the life sciences tools industry. Her stellar career includes: “I am thrilled to join the tremendous team at LevitasBio,” said Dominique Remy-Renou, newly appointed Senior VP of Global Commercial Operations for LevitasBio Europe BV. “Our transformative technology is a gamechanger in the cellular processing and characterization market. I look forward to increasing our field presence and helping to drive our commercial success.” Greg Herrema, Board of DirectorsA Harvard Business School MBA graduate, Mr. Herrema joins the LevitasBio board with extensive experience managing large, global, high tech businesses across a diverse range of products, services, and end markets. His ability to develop and implement growth strategies and his track record for driving commercial performance will bring welcome insights and strategic thinking to LevitasBio. Greg’s roles in Thermo Fisher Scientific included responsibility for multiple multi-billion dollar revenue businesses: “I am excited to join the LevitasBio board of directors. LevitasBio’s innovative approach to the label-free separation of cells at the single-cell level is highly differentiated and their product portfolio offers significant customer value. I look forward to playing a role in enabling LevitasBio’s success.” “We couldn’t be happier to welcome Dominique and Greg to the C-Suite and board of directors, respectively,” stated Martin Pieprzyk, CEO of LevitasBio. “We look forward to their contributions as we become the industry standard in cellular analysis.” ### LevitasBio —True Biology Begins HereOur mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
LevitasBio Completes Series C Financing
MENLO PARK, CA – LevitasBio, Inc. (levitasbio.com), a premier end-to-end sample processing and analysis provider to the life sciences market, announced it has completed Series C round financing of $35 million to advance its mission of providing powerful, industry-leading methods of cellular analysis. The funding allows LevitasBio to accelerate its commercial success through the development of next generation high-throughput instruments for sample processing and analysis. For the first time ever, researchers using LevitasBio’s groundbreaking technology can examine, analyze and understand true biological signatures without altering, stressing, or damaging cells—all while preserving the original samples. This new round of funding was led by Novalis Lifesciences with the participation of Pavilion Capital—a unit of Temasek Holdings Pte, an industry-leading strategic investor, and was supported by existing investor Decheng Capital. “This funding furthers our plans to become the benchmark platform for sample processing workflows,” stated Joe Walthers, LevitasBio VP of Finance. “Our existing life sciences and pharmaceutical development clients overwhelmingly validated the power and success of our technology.” “Novalis is excited to support LevitasBio as it transforms sample processing and analysis. This critical part of the workflow has stymied industry innovation and is underappreciated by the investment community,” said Paul Meister, Partner at Novalis LifeSciences. “We are impressed with LevitasBio’s unique solutions that have been commercialized thus far and, with our investment, will enable their revolutionary advancement of sample preparation and analysis that powers life science research.” Over the last year LevitasBio expanded its impressive portfolio with multiple product developments: Martin Pieprzyk, CEO of LevitasBio, expounded that “Unlike current industry methods that induce alterations, stress or damage that mask the true biology of your sample, LevitasBio solutions preserve the key biological signatures that deliver the most viable and unaltered cells providing researchers clearer data for actionable insights. I believe LevitasBio is expertly positioned to become the de facto industry standard for cellular analysis.” LevitasBio—True Biology Begins HereOur mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained. About Novalis LifeSciences LLCNovalis LifeSciences is an investment and advisory firm for the Life Science industry that was founded in 2017 by Marijn E. Dekkers. With a team of experienced operating executives from the Life Science industry, Novalis funds and advises visionary Life Science entrepreneurs. In addition to making financial investments, Novalis provides strategic and operational advice to portfolio companies that are at a critical growth stage in their development. The firm has approximately $500M in assets under management in two investment funds.www.novalislifesciences.com Contact: Steven CollierCommunication [email protected]
LevitasBio Announces the LeviCell EOS System: A New Era in Sample Processing and Characterization
MENLO PARK, Calif.–(BUSINESS WIRE)–LevitasBio, Inc. today unveiled the LeviCell™ EOS system, their next generation solution for cell separation and enrichment, featuring higher throughput and simultaneous targeted selection of viable cells. Utilizing field proven Levitation Technology, researchers can now effectively scale their experiments up to 16x and process up to 40 million cells per run. The LeviCell EOS System debuts, along with new LeviPrep and LeviSelect product lines for tissue dissociation and targeted cellular selection, at the 2022 American Association for Cancer Research General Meeting held April 8-13 in New Orleans, Louisiana. “The new LeviCell EOS system paves the way for fully integrated approaches to sample processing and accurate characterization at scaled throughputs. This marks a profound shift in how scientists work with their samples.” Tweet this Unprecedented Sample Throughput and Scalability LevitasBio first revolutionized sample preparation in 2020 with the launch of the LeviCell system, which introduced researchers to a gentle, fast, and unbiased method to separate and enrich cells of interest via magnetic levitation. Less than two years later, LevitasBio has addressed researchers’ oft stated desire for scalability, both in the quantity of samples and cells that can be levitated and accessed. The new LeviCell EOS system increases sample throughput by four-fold and enables up to four LeviCell EOS modules to be interconnected and independently controlled, increasing total scalability by 16x. Researchers can now accelerate their discoveries with unprecedented sample processing power and insights. A New Era in Sample Processing The LeviCell EOS system introduces several new features that enhance unbiased sample processing to optimize the study of natural biology. First is an embedded thermal control system, which allow users to select from a range of pre-defined temperatures, ensuring samples are processed at ideal temperatures to maintain cellular states. Additionally, an advanced, fully reticulated imaging system enables powerful, real-time sample characterization analytics during processing. Important insights such as fractionation, cell counts, viability assessment, and quality measurements, can be reviewed real-time, empowering researchers to make informed decisions on how to best utilize their enriched samples in downstream studies. Finally, the LeviCell EOS system delivers unprecedented flexibility with a modular and interchangeable EOS Magnetic Core. A growing family of selectable core modules will enable a broad range of specifically optimized applications on a single platform. “We are changing the landscape of how researchers conduct their experiments,” says Martin Pieprzyk, CEO of LevitasBio. “The new LeviCell EOS system paves the way for fully integrated approaches to sample processing and accurate characterization at scaled throughputs. This marks a profound shift in how scientists work with their samples.” For more information, visit http://levitasbio.com/eos. For collaborations and business development, reach out to us at [email protected]. About LevitasBio LevitasBio has pioneered a new and powerful method of cellular enrichment and analysis. Utilizing proprietary Levitation Technology, our LeviCell platform can accurately and gently detect, quantify, enrich, and test cells. Our unbiased, label-free method can detect cell type and state with minimal time and handling, and has been adopted across a broad range of critical applications, including single cell multi-omics, CRISPR, and cell line development.